No Data
AstraZeneca's Lymphoma Drug Application Secures Priority Review Status in US
AstraZeneca (AZN) Receives a Hold From Jefferies
Express News | AstraZeneca : Jefferies Raises Target Price to $75.5 From $74
Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment
Express News | Arcus Biosciences Inc - AstraZeneca to Sponsor Study on Casdatifan and Volrustomig Combination
AstraZeneca: Strong Sales and Robust Pipeline Underpin Buy Rating
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.